Gladius Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Gladius Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,899	Closed	-$25.5K	–	477
2023 Q1	$25.5K	Sell	1,899 -666	-26%	-$11.5K	﹤0.01%	308
2022 Q4	$31.7K	Buy	+2,565	New	+$36.3K	﹤0.01%	295

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Gladius Capital Management's ICPT Position: Q2 2023 in Review

Gladius Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 1,899 shares — an estimated $25.5K sold.

Gladius Capital Management first reported a position in ICPT in Q4 2022 and held it in 2 quarters. The position peaked at $31.7K in Q4 2022. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Gladius Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Gladius Capital Management sold 1,899 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $25.5K.
Gladius Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
Gladius Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $31.7K in Q4 2022.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.